CYDY cannot do anything except bring in another en

Quote:

---

CYDY cannot do anything except bring in another entity to monetize leronlimab.

---

A distribution partnership would need to be in place for the first approval because the FDA wants to see that and it would be prohibitive with Cytodyn being pre-revenue. Otherwise you're full of crap.

Leronlimab is valuable even pre-approval because of what it's already shown in longhaulers, NASH and mTNBC and the potential it has on a long string of indications. Where leverage exists is in the word no. As in "Your offer sucks, no deal.".

You bring up the bogeyman of "there is no cash" which is no different then the jackasses going on about bankruptcy. Either you expect the price to go up or you're pretty stupid to continue buying. The price goes up and shares can be sold at that higher price. Money in the bank means that trials can be done. Longhaulers should definitely be the first new one.